Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation

Norbert Galldiks^{1

2

3}, Maximilian Niyazi^{4

5}, Jörg-Christian Tonn^{6

5}, Karl-Josef Langen^{2

3

7}

Affiliations

¹ Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
² Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
³ Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
⁴ Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
⁵ German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
⁶ Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
⁷ Department of Nuclear Medicine, RWTH University Hospital Aachen, Aachen, Germany.

Comment

Norbert Galldiks et al. Neuro Oncol. 2021.

. 2021 Aug 2;23(8):1410-1411.

doi: 10.1093/neuonc/noab098.

Norbert Galldiks^{1

2

3}, Maximilian Niyazi^{4

5}, Jörg-Christian Tonn^{6

5}, Karl-Josef Langen^{2

3

7}

¹ Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
² Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
³ Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
⁴ Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
⁵ German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
⁶ Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
⁷ Department of Nuclear Medicine, RWTH University Hospital Aachen, Aachen, Germany.

No abstract available

Comment on

Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.
Galldiks N, Niyazi M, Grosu AL, Kocher M, Langen KJ, Law I, Minniti G, Kim MM, Tsien C, Dhermain F, Soffietti R, Mehta MP, Weller M, Tonn JC. Galldiks N, et al. Neuro Oncol. 2021 Jun 1;23(6):881-893. doi: 10.1093/neuonc/noab013. Neuro Oncol. 2021. PMID: 33538838 Free PMC article.
Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
Kotecha R, Aboian M, Nabavizadeh SA, Parent EE, Trifiletti DM, Chao ST. Kotecha R, et al. Neuro Oncol. 2021 Aug 2;23(8):1408-1409. doi: 10.1093/neuonc/noab097. Neuro Oncol. 2021. PMID: 34081125 Free PMC article. No abstract available.

1. Galldiks N, Niyazi M, Grosu AL, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.. Neuro Oncol. 2021;23(8):881–893. - PMC - PubMed
1. Shoup TM, Olson J, Hoffman JM, et al. Synthesis and evaluation of [¹⁸F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40(2):331–338. - PubMed
1. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-¹⁸F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48(1):56–63. - PubMed
1. Karlberg A, Berntsen EM, Johansen H, et al. ¹⁸F-FACBC PET/MRI in diagnostic assessment and neurosurgery of gliomas. Clin Nucl Med. 2019;44(7):550–559. - PubMed
1. Wakabayashi T, Iuchi T, Tsuyuguchi N, et al. Diagnostic performance and safety of positron emission tomography using ¹⁸F-fluciclovine in patients with clinically suspected high- or low-grade gliomas: a multicenter phase IIb trial. Asia Ocean J Nucl Med Biol. 2017;5(1):10–21. - PMC - PubMed